Immunopeptidomics
Measure HLA-bound peptides from tissue by mass spectrometry, linked to HLA type, tumor DNA and RNA. Keep the spectra and identification confidence—not just a list of predicted binders.
Same patient.
Two views.
One timeline.
We’re seeking clinical and laboratory collaborators to connect measured HLA peptides with mutations tracked over time in the same breast cancer patients.
Discuss feasibilityLongitudinal mutation tracking
Follow tumor-linked variants through serial plasma or repeat tissue sequencing, with matched normal blood, assay sensitivity and treatment context. A mutation in blood does not by itself establish antigen presentation.
The link is the study.
A proposed tumor-cohort design—not a collection schedule. The clinical setting is not yet selected.
| Clinical event | Tissue | Blood | Context |
|---|---|---|---|
| Baseline | HLA-peptide measurement + tumor DNA / RNA | Plasma + matched normal / white blood cells | HLA type, pathology, lesion and pretreatment status |
| During follow-up | Repeat tissue only where available and appropriately approved | Serial plasma at protocol-defined visits | Treatment, collection interval and assay detection limits |
| Surgery or progression | Repeat HLA-peptide measurement + DNA / RNA if usable tissue exists | Time-matched plasma; white-cell controls as needed | Residual disease, sampling site and clinical outcome |
Serial blood can track mutations; repeat tissue measurements are needed to evaluate changes in antigen presentation. No residual tumor or an undetected peptide is not evidence of antigen loss.
Existing pieces.
A missing connection.
Selected published examples, checked September 12, 2026. These are external studies, not Tesserie datasets or partners.
Breast tumor immunopeptidomes
26 primary tumor samplesMeasured HLA peptides and RNA sequencing; PRIDE PXD034818, SRA PRJNA852282.
Still neededNo matched longitudinal mutation series established in this release.
View the sourceTNBC evolution during chemotherapy
20 patientsLongitudinal tumor sequencing; BioProject PRJNA396019.
Still neededNo measured HLA immunopeptidomics described in this dataset.
View the sourceI-SPY 2 serial ctDNA study
84 patients · 291 plasma samplesPublished longitudinal ctDNA analysis; 58 patients had all four timepoints. Further data or specimen access requires a feasibility and approval process.
Still neededNo matching tumor HLA-peptide dataset verified. Residual tissue and variant-level access must be confirmed.
View the sourceThese counts cannot be added into a matched cohort. We have not verified an accessible breast cancer dataset that meets the complete paired design above. A published cohort size is not a count of samples available to Tesserie.
From an introduction
to a feasible study.
- 01
Check what overlaps
Start with aggregate counts: patients with suitable tissue, sequencing, serial samples and documented permissions. No patient records are needed for the first conversation.
- 02
Co-design a small feasibility study
An investigator and assay lab define the population, tissue requirements, quality checks, costs and decision criteria before committing scarce samples.
- 03
Work under institutional governance
Resolve ethics review, consent or applicable waivers, data and material agreements, commercial-use terms and secure analysis before any transfer or new collection.
Clinicians · Assay labs · Tissue banks
Is there a fit?
We’re looking for an investigator-led cohort, an immunopeptidomics lab and normal or high-risk tissue expertise. Scientific leadership is also a current priority.
Introduce your institution, role and relevant capabilities. We’ll start with a non-confidential feasibility conversation; the study scope and each party’s contribution remain to be agreed.
Email about a collaborationOpens your email app; nothing is submitted by this page. Do not send patient records, genomic files or identifying information. No study recruitment, medical uploads or institutional partnership is being announced.